We provide preclinical data that show how primary human T cells from a range of healthy donors can be engineered to express a CD1c-restricted, mLPA-specific TCR and used for effective adoptive immunotherapy of acute leukemia in mice, without any clear side-effects assessable within the limitations of human xenograft models in immunodeficient animals. The gene discussed is CD1C; the disease is acute leukemia.